Clinical Trials Open for Breast Cancer Patients

Phone (630) 654 1790 Fax (630) 654 1845

Hinsdale Hematology Oncology Seeks Participants for a Double-blind, Randomized, Phase 2b Research Trial for Women Diagnosed with Locally Recurrent Metastatic Breast Cancer (NU 07B1)

What will the study evaluate?

Two FDA-approved medications that have shown to have significant anti-tumor activity in subjects with cancer
The effectiveness of the combination of the two medications
How well subjects tolerate the treatment
How a subject’s quality of life is affected during treatment

What are the requirements for participation in the study?

The study is open to women who:

Are 18 years of age or older
Have breast cancer
Are not pregnant
Agree to use adequate contraception (barrier method of birth control) before and during the study
Are able and willing to sign a written informed consent

How long is the study?
The study will consist of a screening period, a treatment period, and follow-up period.

Does participation in the study cost anything?
Commercial paclitaxel and study medication will be provided to subjects. The subject will not be charged for visits or procedures strictly for the purpose of the study. Normal standard of care visits or procedures that would have occurred whether or not the subject participated in the study will be billed to the subject or the subject’s insurance.

Will subjects be paid for participation?
No. Subjects will not be paid.

For further information or to express interest in this important research study, please call Jan Wilson at 630-654-1790.

This research study is being made available to select oncology practices through the Accelerated Community Oncology Research Network (ACORN).

For Immediate Release

Hinsdale Hematology Oncologys Seeks Participants for Locally Recurrent Metastatic Breast Cancer Study

Hinsdale Hematology Oncology is one of approximately 50 sites nationally that will evaluate investigational treatment options for women diagnosed with Locally Recurrent or Metastatic Breast Cancer.

Limited to approximately 180 subjects, the study will look at two medications that have shown to have significant anti-tumor activity in subjects with cancer. Both have been approved by the United States Food and Drug administration (FDA) for certain types of cancer. The purpose of this study is to evaluate the effectiveness of combining the two medications. The study also seeks to determine how well subjects tolerate the treatment, and it evaluates how the treatment affects a subject’s quality of life.

Women participating in the study must have breast cancer and be 18 years of age or older. Additionally, Subjects must not be pregnant and must agree to use adequate contraception (barrier method of birth control) before and during the study. Subjects must be able to swallow oral medication. Finally, Subjects must be willing and able to sign a written informed consent.

Women participating in the study will be provided commercial paciltaxel and study medication. The subject will not be charged for visits or procedures strictly for the purpose of the study. Normal standard of care visits or procedures that would have occurred whether or not the subject participated in the study will be billed to the subject or the subject’s insurance. The study will consist of a screening period, a treatment period, and a follow-up period. Subjects will not be paid.

For further information or to express interest in this research study, please call Jan Wilson at 630-654-1790.

Dr. Elyse Schneiderman of Hinsdale Hematology Oncology will direct the research study which is being made available to select oncology practices through the Accelerated Community Oncology Research Network (ACORN).

Follow us on Facebook and read our new Blog:

Click here to join our mailing list: